Chemotherapeutic Evaluation of a Synthetic Tubulysin Analogue-Dendrimer Conjugate in C26 Tumor Bearing Mice

William C. Floyd, Gopal K. Datta, Shinichi Imamura, Heidi M. Kieler-Ferguson, Katherine Jerger, Andrew W. Patterson, Megan E. Fox, Francis C. Szoka*, Jean Frechet, Jonathan A. Ellman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Conjugate to ameliorate! Polymeric drug delivery using a synthetic tubulysin analogue in C26 tumor bearing mice is described. A single dose of this conjugate (shown) resulted in a 90 % increase in the average lifespan of the mice as compared to groups given a phosphate-buffered saline control or the free tubulysin analogue. Moreover, 37 % of the mice given the polymeric formulation were tumor free at the conclusion of the study.

Original languageEnglish (US)
Pages (from-to)49-53
Number of pages5
JournalChemMedChem
Volume6
Issue number1
DOIs
StatePublished - Jan 3 2011

Keywords

  • Antitumor agents
  • Colon carcinoma
  • Dendrimers
  • Drug delivery
  • Tubulysins

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Chemotherapeutic Evaluation of a Synthetic Tubulysin Analogue-Dendrimer Conjugate in C26 Tumor Bearing Mice'. Together they form a unique fingerprint.

Cite this